June 1, 2026 — Sirona Medical and Everlight Radiology have announced a five-year strategic partnership where Everlight will deploy Sirona's RadOS platform — a unified, cloud-native radiology workflow solution — across its entire global operation. The platform will replace its existing PACS and reporting solutions in Australia, New Zealand, Ireland, the United Kingdom, the UAE and South Africa. The commercial partnership is Sirona's first partnership outside the United States and is one of the largest radiology platform agreements ever signed.
"This partnership marks the beginning of the cloud-native era in radiology software globally," said Andy Donaldson, chief technology officer, Everlight Radiology. "Sirona has delivered an architecture that is fundamentally different from anything else in the market today – Sirona is unified, and cloud-native from the ground up. For teleradiology, that architectural distinction is existential, not incremental."
"Everlight has built one of the most technologically and operationally exceptional radiology practices in the world," said Ken Kaufman, chief executive officer, Sirona Medical. "We're thrilled to be their partner as they continue their unprecedented growth in the global market, and to work with them to deliver the AI-powered future of radiology to patient care globally."
In addition to adopting Sirona's existing Platform AI suite, the two businesses will develop and implement industry-first agentic AI automations across Everlight's network aimed at improving both clinical and operational efficiency at global scale.
"Through Sirona's platform, Everlight will be able to build and deploy AI-powered automations across clinical, administrative, and operational workflows," said Jeff Oakman, global chief operating officer, Everlight Radiology. "This partnership will fundamentally transform how our radiologists practice, and position Everlight at the forefront of AI-enabled diagnostic medicine globally."
"Sirona was founded to accelerate the transition to AI-powered healthcare globally, and our partnership with Everlight has accelerated this mission by years," said Cameron Andrews, founder and president, Sirona Medical. "Thanks to Everlight, patients and doctors outside the U.S. will benefit from technologies that would not have been exported for years. Everlight is leading the AI age globally, and we're proud to now be their partner in doing so."
"Technology and culture have always been the foundation of Everlight's success," said Rob Anderson, CEO, Everlight Radiology. "Sirona is the only enterprise-grade cloud-native platform in radiology today. Our partnership will allow Everlight to do what we've always done: deliver quality care to patients anywhere, and the best clinical tools to our doctors everywhere."
Sirona, Everlight Radiology Partnership
-
Unified, Cloud-Native PACS & Reporting: Everlight will replace its existing radiology imaging technology stack with Sirona's RadOS platform, integrating diagnostic viewing, reporting, PACS archive, worklist, and AI into a single cloud-native platform accessible from any browser, anywhere in the world.
-
Global Scale: The deployment spans six markets (Australia, New Zealand, Ireland, the United Kingdom, the United Arab Emirates, and South Africa) with doctors on six continents, making it one of the most geographically expansive radiology platform deployments in history.
-
AI-Native Architecture: Everlight will gain access to Sirona's embedded AI orchestration layer and Amplify SDK, enabling the practice to build, deploy and manage proprietary AI workflows across clinical and operational use cases.
-
Product Partnership: Sirona and Everlight will further develop and deliver Sirona's Agentic AI platform, and will collaborate on the design and development of other valuable features and workflows.
-
In-House R&D: Everlight will build bespoke software and AI capabilities on top of Sirona's RadOS platform, leveraging Sirona's Platform Intelligence capabilities to build unique clinical and operational efficiencies, and other sources of competitive advantage.
May 20, 2026 
